Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine added to standard quadruple therapy for Helicobacter pylori eradication
IRCT20141209020258N103Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in Helicobacter pylori infection (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Eradication of Helicobacter infection. Started Mar 2018; status: completed.
02
Drugs
acetylcysteine
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20141209020258N103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N103.